COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02174679
Expanded Access Status : No longer available
First Posted : June 25, 2014
Last Update Posted : June 4, 2019
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Tracking Information
First Submitted Date June 20, 2014
First Posted Date June 25, 2014
Last Update Posted Date June 4, 2019
Descriptive Information
Brief Title 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Brief Summary To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed Description This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Study Type Expanded Access
Intervention Drug: 68Ga DOTATATE
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
Other Name: 68Ga DOTATATE PET/CT Scan
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT02174679
Responsible Party Jonsson Comprehensive Cancer Center
Study Sponsor Jonsson Comprehensive Cancer Center
Collaborators Not Provided
Principal Investigator: Johannes Czernin, MD University of California, Los Angeles
PRS Account Jonsson Comprehensive Cancer Center
Verification Date May 2019